Summary
A hyperkinetic heart syndrome has been diagnosed in 10 patients by clinical investigation and right-heart catheterization at rest and during exercise. Subsequently, the patients received 3×40 mg alinidine, and 2×40 mg propranolol and placebo, each for 2 weeks in a double-blind cross-over study.
Heart rate at rest (P<0.05) and during exercise (P<0.001) decreased significantly under alinidine and propranolol to the same extent (control, 83/170; alinidine, 68/146; propranolol, 73/139; placebo, 83/162 beats per min). Lower limb flow at rest and after exercise, measured by plethysmography, as well as left-ventricular fractional shortening and mean velocity of circumferential fiber shortening, measured by echocardiography, decreased insignificantly.
Sedation and a dry mouth occurred in six patients under alinidine, while fatigue and cold hands and/or feet were reported by five patients under propranolol. Thus, alinidine may be used as an alternative to beta-blocking in the treatment of the hyperkinetic heart syndrome.
Similar content being viewed by others
Abbreviations
- A:
-
Behandlung mit Alinidine
- B:
-
Behandlung mit Propranolol
- B1–B6 :
-
Belastungsminuten
- E1–E5 :
-
Erholungsminuten
- FS%:
-
prozentuale linksventrikuläre Verkürzungsfraktion
- HF:
-
Herzfrequenz
- K:
-
Kontrolluntersuchung
- Li:
-
Liegen
- LVEDD:
-
linksventrikulärer enddiastolischer Durchmesser
- LVESD:
-
linksventrikulärer endsystolischer Durchmesser
- P:
-
Behandlung mit Placebo
- St:
-
Stehen
- TM-Mode:
-
time-motion-mode
- Vcf:
-
mittlere zirkumferentielle Faserverkürzungsgeschwindigkeit
Literatur
Arndts D, Forster HJ (1981) New aspects in the metabolism of alinidine in man. Eur J Drug Metab Pharmakokin 6:313–315
Bollinger A, Gander M, Forster G (1965) Pulsfrequenz und Leistungsfähigkeit vor und nachβ-Rezeptoren-Blockade durch Propranolol. Schweiz Med Wochenschr 95:1075–1079
Bollinger A, Gander M, Pylkkänen, Forster G (1966) Treatment of the hyperkinetic heart syndrome with propranolol. Cardiologia 49 (Suppl 2):68–82
Bollinger A, Simon HJ (1976) Einfluß adrenergischerβ-Rezeptoren-Blockade auf die Unterarmdurchblutung bei Patienten mit hyperkinetischem Herzsyndrom und vegetativer Ruhetachykardie. Dtsch Med Wochenschr 92:28–30
Bollinger A (1969) Durchblutungsmessungen in der klinischen Angiologie, mit besonderer Berücksichtigung der Venenverschluß-Plethysmographie. Series Angiologica, Band IV, Huber, Bern
Brachfeld N, Gorlin R (1960) Idiopathic hyperkinetic state: a new clinical syndrome. Br Heart J 22:353–360
Delius L (1972) Funktionelle kardiovaskuläre Störungen. Internist 13:1–6
Fiorentini C, Olivari MT, Moruzzi P, Guazzi MD (1981) Long-term follow up of the primary hyperkinetic heart syndrome. An echocardiographic and hemodynamic study. Am J Med 71:221–227
Frohlich ED (1971) Beta adrenergic blockade in the circulatory regulation of hyperkinetic states. Am J Cardiol 27:195–199
Gillium RF, Teichholz LE, Herman MW, Gorlin R (1981) The idiopathic hyperkinetic heart syndrome: clinical course and long-term prognosis. Am Heart J 102:728–734
Gorlin R, Brachfeld N, Turner JD, Messer JV, Salazar E (1959) The idiopathic high cardiac output state. J Clin Invest 38:2144–2153
Gorlin R (1962) The hyperkinetic heart syndrome. J Am Med Assoc 182:823–829
Guazzi M, Polese A, Magrini F, Fiorentini C, Olivari MT (1975) Long-term treatment of the hyperkinetic heart syndrome with propranolol. Am J Med Sci 270:465–474
Harron DWG, Riddel JG, Shanks RG (1981) Cardiovascular effects of alinidine (ST 567) in healthy volunteers. Br J Clin Pharmacol 11:116–117
Harron DWG, Shanks RG, Riddel JG (1981) Alinidine reduces heart-rate without blockade of beta adrenoceptors. Lancet 1, 1981:351–353
Harron DWG, Jady K, Riddel JG, Shanks RG (1982) Effects of alinidine, a novel bradycardic agent, on heart rate and blood pressure in man. J Cardiovasc Pharmacol 4:213–220
Harron DWG, Arndts D, Shanks RG (1982) Alinidine pharmakokinetics following acute and chronic dosing. Br J Clin Pharmacol 13:821–827
Harron DWG, Arndts D, Finck M, Shanks RG (1983) An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine. Br J Clin Pharmacol 16:451–455
Henry WL, Ware J, Gardin JM, Hepner SJ, McKay J, Weisner M (1978): Echocardiographic measurement in normal subjects: growth related changes that occur between infancy and early adulthood. Circulation 57:278–285
Holmgren A, Jonsson B. Levander M, Lindesholm H, Sjöstrand T, Ström G (1957) Low physical working capacity in suspected heart cases due to inadequate adjustment of peripheral blood flow (vasoregulatory asthenia). Acta Med Scand 163:413–421
Juchems R, Wertz U (1969) Zentrale Hämodynamik des hyperkinetischen Syndroms unter Betarezeptorenblockade. Münch Med Wochenschr 111:2567–2571
Kaltenbach M, Becker HJ, Brunn V (1968) Beeinflussung der körperlichen Leistungsfähigkeit und der Muskeldurchblutung durch Beta-Receptorenblocker bei hyperkinetischer Kreislaufregulationsstörung. Verh Dtsch Ges Inn Med 74:565–568
Kaltenbach M (1974) Die Belastungs-Untersuchung von Herzkranken. Studienreihe Boehringer Mannheim
Kobinger W, Lillie C (1984) Alinidine. In: Scriabine A (Hrsg) New drugs annual: cardiovascular drugs Vol. 2, Raven Press, New York, pp 193–210
Lohmöller G, Albrecht A, Lydtin H (1970) Plethysmographische Untersuchungen über die Wirkung derβ-Receptorenblocker Propranolol und Practolol auf die Unterschenkeldurchblutung bei Gesunden und Patienten mit hyperkinetischem Herzsyndrom. Verh Dtsch Ges Inn Med 76:927–930
Lydtin H, Schnelle K, Lohmöller G, Kusus T (1969) Über Diagnose und Therapie des hyperkinetischen Herzsyndroms. Verh Dtsch Ges Inn Med 75:402–405
Lydtin H (1974) Das hyperkinetische Herzsyndrom. Therapiewoche 20:2274–2278
Magometschnigg (1981) Das hyperkinetische Herzsyndrom. Hämodynamische und pathologische Untersuchungen bei Anwendung pharmakologischer und therapeutischer Maßnahmen. Angiocardiology 3:244–261
Sachs L (1983) Angewandte Statistik, 6. Auflage, Springer, Berlin Heidelberg New York
Siegl PKS, Wenger HC, Sweet CS (1984) Comparison of cardiovascular responses to the bradycardic drugs, alinidine, AQ-A 39, an mixidine, in the anesthetized dog. J Cardiovasc Pharmacol 6:565–574
Simoons ML, Hugenholtz PG (1984) Haemodynamic effects of alinidine, a specific sinus node inhibitor, in patients with unstable angina or myocardial infarction. Eur Heart J 5:227–232
Stanek B, Reiterer W, Placheta P, Raberger G (1983) Acute effects of alinidine on heart rate and blood pressure in healthy subjects and patients with hyperkinetic heart syndrome. Eur J Clin Pharmacol 24:31–34
Wiegand VW, Meinertz T, Kasper W, Jähnchen E (1981) Determination of alinidine in human plasma by high-performance liquid chromatography. Chromatogr 223:238–242
Author information
Authors and Affiliations
Additional information
Die Arbeit enthält Teile der Dissertation von G. Degoutrie
Rights and permissions
About this article
Cite this article
Schräder, R., Degoutrie, G., Landgraf, H. et al. Behandlung des hyperkinetischen Herzsyndroms mit Alinidine und Propranolol. Klin Wochenschr 65, 69–75 (1987). https://doi.org/10.1007/BF01745476
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01745476